Oragenics, Inc.

Latest News

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Innovative Biopharmaceuticals for Infectious Diseases

Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease.

Learn More About Oragenics

Oragenics Acquires Noachis Terra, Inc.

NIH-created SARS-CoV-2 (COVID-19) Spike Protein Vaccine Technology could provide specific immunity from the novel coronavirus (“SARS-CoV-2”), the root cause of coronavirus disease 2019 (“COVID-19”).

Learn More about the Acquisition of Noachis Terra

Fighting Global Bacterial Antibiotic Resistance

Oragenics is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans.

Learn More About Lantibiotics

Sign up for email updates

Be the first to receive breaking news

Sign Up